Breaking News Headlines Today | Ground News

See every side of every news story

contemporarypediatrics.com image

News from contemporarypediatrics.com

contemporarypediatrics.com’s media bias is unknown. Ground News is unable to assign a bias rating and does not have ratings available from Ad Fontes Media, All Sides, and Media Bias/Fact Check.

contemporarypediatrics.com’s factuality rating is Unknown. Ground News calculates this rating using a combination of the fact and reliability ratings from Ad Fontes Media and Media Bias/Fact Check.

Information about contemporarypediatrics.com

Where is contemporarypediatrics.com located?contemporarypediatrics.com's Website

Media Bias Ratings

Do you disagree?

Edit bias

Learn more about Media Bias Ratings.

Factuality

Learn more about Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Top contemporarypediatrics.com News

Routine Wellness Visits Reveal Hidden Asthma Cases Through Community-Wide Screening

Medical · Bakersfield

Routine Wellness Visits Reveal Hidden Asthma Cases Through Community-Wide Screening

56% Center coverage: 16 sources

Researchers were able to identify more patients with asthma in specific communities by screening all children during routine wellness visits and asking about potential home environmental triggers, according to new research.See the Story

Golf Cart Injuries On The Rise Among Kids

Golf · United States

Golf Cart Injuries On The Rise Among Kids

38% Left coverage: 8 sources

Key Takeaways See the Story

First-Ever IL-23 Inhibitor: J&J's TREMFYA Approved for Children with Psoriasis, Shows 56% Clearance Rate

Johnson & Johnson · United States

First-Ever IL-23 Inhibitor: J&J's TREMFYA Approved for Children with Psoriasis, Shows 56% Clearance Rate

FDA approves TREMFYA for children 6+ with plaque psoriasis and psoriatic arthritis. Study shows 56% achieved PASI 90 vs 16% placebo. Impacts 20,000 children under 10 annually.See the Story

Breaking News Topics Related to contemporarypediatrics.com